7 completed, 2 recruiting, 2 terminated. 11 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 7, Recruiting 2, Terminated 2 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow Recurrent Small Cell Lung Cancer: new trials by email Literature Review of Recurrent Small Cell Lung Cancer trials Research Report on Recurrent Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine - Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | Phase 1 | Recruiting | National Cancer Institute (NCI) | 40 | 2026-10-16 | 2026-10-29 |
| Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC Stenoparib/Temozolomide, Lurbinectedin - Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 166 | 2026-02-23 | 2026-03-11 |
| Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC Nivolumab, Ipilimumab, Lurbinectedin - Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer | Phase 1 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 9 | 2020-11-23 | 2024-04-02 |
| CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer 6,8-bis(benzylthio)octanoic acid - Recurrent Small Cell Lung Cancer | Phase 1 | Completed | Wake Forest University Health Sciences | 15 | 2013-10-01 | 2018-07-03 |
| Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer Rovalpituzumab tesirine (SC16LD6.5) - Recurrent Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Stemcentrx | 82 | 2013-07-01 | 2018-08-09 |
| Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer questionnaire administration, quality-of-life assessment, counseling intervention - Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 1 | Completed | Wake Forest University Health Sciences | 6 | 2011-01-01 | 2018-08-01 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors temsirolimus, vinorelbine ditartrate - Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma | Phase 1 | Completed | University of Southern California | 19 | 2010-06-01 | 2016-06-13 |
| Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors obatoclax mesylate, topotecan hydrochloride, laboratory biomarker analysis - Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2007-08-01 | 2015-05-05 |
| Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, docetaxel - Extensive Stage Small Cell Lung Cancer, Recurrent Colon Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 60 | 2004-06-01 | 2014-03-31 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis - Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2001-12-01 | 2013-09-30 |
| Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors trastuzumab, paclitaxel, recombinant interleukin-12 - Male Breast Cancer, Recurrent Breast Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 18 | 2001-11-01 | 2013-06-04 |
Small Cell Lung Carcinoma (11) · Carcinoma, Non-Small-Cell Lung (5) · Breast Neoplasms (3) · Carcinoma, Ovarian Epithelial (3) · Endometrial Neoplasms (3) · Breast Neoplasms, Male (2) · Colonic Neoplasms (2) · Prostatic Neoplasms (2) · Rectal Neoplasms (2) · Stomach Neoplasms (2) · Uterine Cervical Neoplasms (2) · Anus Neoplasms (1) · Appendiceal Neoplasms (1) · Bile Duct Neoplasms (1) · Carcinoma, Hepatocellular (1)
Bronchial Neoplasms (11) · Carcinoma, Bronchogenic (11) · Lung Diseases (11) · Lung Neoplasms (11) · Neoplasms (11) · Neoplasms by Site (11) · Respiratory Tract Diseases (11) · Respiratory Tract Neoplasms (11) · Thoracic Neoplasms (11) · Carcinoma (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Adenocarcinoma (3)
PM 01183 (2) · 7-hydroxystaurosporine (1) · Counseling (1) · Cyclophosphamide (1) · Docetaxel (1) · Early Intervention, Educational (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Interleukin-12 (1) · Interleukin-12 Subunit p35 (1) · Ipilimumab (1) · Irinotecan (1) · Methods (1) · Nicotine Replacement Therapy (1) · Nivolumab (1) · Paclitaxel (1)
National Cancer Institute (NCI) (5) · Wake Forest University Health Sciences (2) · H. Lee Moffitt Cancer Center and Research Institute (1) · Stemcentrx (1) · University of Southern California (1) · VA Office of Research and Development (1)
United States (11)
Agustin Garcia (1) · Alberto A Chiappori, MD (1) · Donald Strickland, MD (1) · Jimmy Ruiz (1) · John Marshall (1) · Kathryn Weaver (1) · Lee Krug (1) · Nicholas P Tschernia, M.D. (1) · Paula Fracasso (1) · Shadia Jalal, MD (1) · William Carson (1)
P30CA012197 (1), P30CA044579 (1), P30CA051008 (1), R01CA088972 (1), U01CA076576 (1)